Clinical trial
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of…
NCT00477035 · Sally Arai, Other · Completed
Key facts
| NCT number | NCT00477035 |
|---|---|
| Title | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies |
| Official title | A Phase I Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies |
| Lead sponsor | Sally Arai, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan |
| Enrollment | 22 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | May 22, 2007 |
| Last update posted | Jan 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: